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Abstract
Aim The purpose of the study was to determine the lung
toxicity caused by amiodarone (AD) and bleomycin (BLM)
in rats, by means of Tc-99m HMPAO lung scintigraphy.
Methods Thirty albino rats were randomly divided into
five groups. After AD or BLM was dissolved with isotonic
saline (SF), a 0.5 ml solution was applied to the right
bronchus via a catheter. Group 1 (n = 5 rats) received a
single dose of AD, group 2 (n = 5) received two doses of
AD, group 3 (n = 9) received BLM, group 4 (n = 3)
received hydrochloric acid (HCl), and group 5 (n = 8)
received SF. Rats in groups 1, 2, 3 and 5 were given
37 MBq Tc-99m HMPAO from the tail vein on days 7, 14,
21 and 28, and at 4 and 24 h in group 4. Static images of
10 min duration were obtained at 30 and 60 min by a
double-headed gamma camera (Infinia, GE, Tirat Hacer-
mel, Israel) on 256 9 256 matrix. Regular regions of
interests were drawn over the right lung (RL), left lung
(LL) and the liver (Li), and lung/liver (L/Li) ratios were
calculated. After the scintigraphic imaging procedures
were completed, rats were killed. Lung tissues were eval-
uated on a scale of (?) to (?????) for edema, alveolar
structural integrity and infiltration by inflammatory cells.
Results Groups 2 and 3 showed statistically significant
differences in RL/Li and LL/Li ratios, whereby RL/Li was
higher than LL/Li (p \ 0.05). There were no significant
differences in RL/Li and LL/Li ratios in group 5
(p [ 0.05). In histopathological examination, minimal
damage or artifacts were observed in group 5. In group 4,
almost all pathological findings were present in the right
lung. Statistically significant (p \ 0.01) histological dif-
ferences were found when groups 1 and 5 were compared.
More significant (p \ 0.001) pathological effects were
noted when groups 2 and 3 were compared to both groups 5
and 1. Injury was more prominent in the lung tissues of the
control rats that were given HCl. Increased RL/Li ratios
and histopathological findings were consistent.
Conclusion Tc-99m HMPAO lung scan are found to be
useful in the identification of patients with lung toxicity.
The simplicity of the procedure and lower radiation
exposure are the advantages of Tc-99m HMPAO lung scan.
Keywords Tc-99m HMPAO lung scintigraphy 
Bleomycin  Amiodarone  Lung toxicity  Rat
Introduction
Technetium D, L-hexamethylpropylene amine oxime (Tc-
99m HMPAO) can easily permeate the pores in the cell
membrane because of its lipophilic characteristic, reach the
endothelial cytoplasm and can detect early and minimal
lung damage. Essentially, it is localized in the lung endo-
thelia. Tc-99m HMPAO penetrates into the alveolar mac-
rophage. Alveolar integrity can be impaired due to some
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lung diseases, systemic diseases and medications. There
are several studies that showed an increase in Tc-99m
HMPAO uptake of the lungs as a result of the impairment
of alveolar integrity [1–5].
Lung toxicity is a frequent side effect of some medi-
cations. Bleomycin (BLM) is an antitumorigenic antibiotic
derived from Streptomyces verticillus. The rate of lung
damage in patients using BLM varies between 2 and 46 %
and may be fatal in 1–2 % of the patients [6–10]. Amio-
darone (AD) is a class 3 anti-arrhythmic benzofuran
derivative that is used in life-threatening ventricular
arrhythmia and atrial fibrillation. The incidence of AD-
induced lung toxicity varies between 1 and 17 % [11–18].
One major complication limiting the use of BLM and AD
is lung toxicity, which is difficult to diagnose by conven-
tional methods [1–5].
The purpose of the present study was to create AD-
induced and BLM-induced lung toxicities in rats and to
confirm this toxicity by scintigraphic imaging using Tc-
99m HMPAO. We believe that it is possible to non-inva-
sively diagnose and follow the lung toxicity that may occur
in patients in the early stages.
Materials and methods
After receiving the approval of Board of Ethics for Animal
Research of our hospital, we started the research with 30
healthy male Albino rats (Ege University Center for
Experimental Animals, Turkey) weighing between 250 and
300 g. The rats were randomly divided into 5 groups. The
rats were weighed, placed in the supine position under
(intraperitoneal) anesthesia [ketamine: 75 mg/kg (Pfizer,
Turkey) and xylazine: 10 mg/kg (Sigma, Aldrich, USA)].
Under a dissection microscope (Mo¨ller-Weder, Germany),
a transverse skin incision was made and the subcutis was
dissected until the trachea was visible. A transverse inci-
sion was made by iris scissors (Auriga, Pakistan) 2–3 rings
below the thyroid cartridge and rats were intubated using
an appropriate polyethylene catheter.
After dissolving in saline, 0.5 ml of medications were
administered to the rats in group 1 through the catheter into
the right bronchus. A 1.83 mmol single dose of AD (1 g,
Sigma-Aldrich, USA) was dissolved in distilled water at
65 C and given to the right bronchus of rats. At the end of
the first week, one of the rats died, resulting in a total of 4
rats in group 1.
Group 2 comprised five rats. A double dose of AD was
administered; first dose was followed by the second dose
after 48 h, using the same method.
Group 3 comprised 9 rats, and they were administered
single dose of BLM (15U, Fluka, Sigma-Aldrich, USA) at
7.5 U/kg.
The positive control group was group 4, consisted of 3
rats. They were administered a single dose of HCl (1 cc/kg
0.1 N HCl).
Group 5 comprised 8 rats and a single dose of isotonic
saline (SF) was administered to the right bronchus of the
rats [19, 20].
Tc-99m HMPAO (Ceretec, Amersham, UK) was pre-
pared by adding 1110 MBq of freshly eluted Tc-99m
pertechnetate to 5 ml of saline solution. Quality control
was conducted using a thin layer chromatography method.
The labeling efficiency of Tc-99m HMPAO was found to
be 90 % and over.
Rats in groups 1, 2, 3 and 5 were administered 37 MBq
of Tc-99m HMPAO from the tail vein, on days 7, 14, 21
and 28. Tc-99m HMPAO scans were performed using a
double-headed gamma camera (Infinia, GE, Tirat Hacer-
mel, Israel) equipped with low-energy high-resolution
parallel-hole collimators. Data were acquired at 30 and
60 min in 256 9 256 matrix using a zoom factor of 1.5. A
static anterior image of 10 min in duration was obtained.
Thirty-seven MBq of Tc-99m HMPAO was injected
from the tail vein to the rats in group 4 and following the
administration at 4 and 24 h, scintigraphic imaging was
conducted for 10 min.
On the anterior scintigraphic images, regular areas of
interest were marked on both of the lungs and liver and the
mean values were calculated to evaluate lung toxicity.
These values were used to determine right lung/liver (RL/
Li) and left lung/liver (LL/Li) ratios.
On day 28, the rats that had the scintigraphic imag-
ing were killed with intraperitoneal injection of high-
dose ketamine (50 mg/kg 9 VA) and xylazine (5 mg/
kg 9 VA) and their lungs were removed. The lung sam-
ples were bisected, fixed in formalin for 24 h, hydrated
through a graded series of ethanol and embedded in par-
affin. Five lm thick sections were deparaffinized and
stained with hematoxylin–eosin (H–E). The sections were
examined under a light microscope (Olympus BX-40) and
photographed by an observer blind to the groups. The
images were transferred onto a computer for morphometric
analyses [21].
Using a blind design, sections were analyzed for edema,
alveolar destruction and the infiltration by the inflamma-
tory cells. According to this analysis, lung damage was
graded as: normal or technical damage (?), congestion
(??), vascular congestion and interstitial edema (???),
minimal damage in alveolar structure and minimal infil-
tration of inflammatory cells (????), massive damage in
alveolar structure and massive infiltration of inflammatory
cells (?????). SPSS 11 was used for statistical analysis.
For the comparison of the RL/Li and LL/Li ratios,
paired t test was used. A statistical significance level of
0.05 was adopted.
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Results
The RL/Li, LL/Li ratios and p values of rats in group 1 are
given in Table 1. A statistical significant difference was
observed in RL/Li and LL/Li ratios of rats in group 1 taken
on day 7 both at 30 and 60 min values (p \ 0.03).
Although the RL/Li ratio on day 14 was significantly
higher than the LL/Li ratio at 30 and 60 min in group 1
rats, the difference was not statistically significant
(p [ 0.05). The RL/Li and LL/Li ratios on days 21 and 28
showed statistically significant differences only at 30 min
(p \ 0.004).
The RL/Li, LL/Li ratios and p values of rats in group 2
are given in Table 2. In group 2, RL/Li and LL/Li ratios
showed statistically significant differences on days 7 and
21, both at 30 and 60 min values (p \ 0.05). The RL/Li
and LL/Li ratios were significant at 30 min on day 14, and
at 60 min on day 28 (p \ 0.05) (Fig. 1). Although there
were no significant differences for the other ratios, the RL/
Li ratios were higher than the LL/Li ratios.
The RL/Li, LL/Li ratios and p values of rats in group 3
are given in Table 3. Statistically significant differences
were observed between the RL/Li and LL/Li ratios calcu-
lated on days 7, 14, 21 and 28, both at 30 and 60 min
(p \ 0.05) (Fig. 2).
Table 1 RL/Li, LL/Li ratios and p values of rats in group 1
Single dose amiodarone
RL/Li LL/Li p value
Day 7 (5 rats)
30 min 0.86 ± 0.06 0.75 ± 0.06 0.030*
60 min 0.82 ± 0.14 0.72 ± 0.16 0.032*
Day 14 (4 rats)
30 min 0.84 ± 0.10 0.72 ± 0.15 0.054
60 min 0.81 ± 0.16 0.73 ± 0.19 0.140
Day 21 (4 rats)
30 min 0.83 ± 0.09 0.73 ± 0.08 0.004*
60 min 0.83 ± 0.07 0.77 ± 0.081 0.120
Day 28 (4 rats)
30 min 0.74 ± 0.14 0.61 ± 0.16 0.0014*
60 min 0.73 ± 0.14 0.68 ± 0.11 0.320
RL right lung, LL left lung, Li liver
* p B 0.05
Table 2 RL/Li, LL/Li ratios and p values of rats in group 2
Two dose amiodarone (5 rats)
RL/Li LL/Li p value
Day 7
30 min 0.87 ± 0.07 0.77 ± 0.007 0.038*
60 min 0.93 ± 0.02 0.83 ± 0.04 0.0045*
Day 14
30 min 0.82 ± 0.18 0.76 ± 0.16 0.040*
60 min 0.88 ± 0.07 0.77 ± 0.12 0.055
Day 21
30 min 0.78 ± 0.07 0.67 ± 0.06 0.021*
60 min 0.79 ± 0.07 0.72 ± 0.05 0.0039*
Day 28
30 min 0.78 ± 0.07 0.71 ± 0.10 0.054
60 min 0.75 ± 0.06 0.66 ± 0.08 0.006*
RL right lung, LL left lung, Li liver
* p B 0.05
Fig. 1 Anterior scintigraphic images of the rats that received two
doses Amiodarone, obtained at 30 and 60 min using Tc-99m HMPAO
14 days after the administration and the areas of interest. ROI 1 right
lung, ROI 2 left lung, ROI 3 liver
Table 3 RL/Li, LL/Li ratios and p values of rats in group 3
Bleomycin (9 rats)
RL/Li LL/Li p value
Day 7
30 min 0.66 ± 0.20 0.54 ± 0.13 0.0200*
60 min 0.62 ± 0.17 0.51 ± 0.16 0.0002*
Day 14
30 min 0.73 ± 0.18 0.60 ± 0.16 0.0002*
60 min 0.71 ± 0.14 0.55 ± 0.10 0.0001*
Day 21
30 min 0.71 ± 0.16 0.54 ± 0.12 0.0003*
60 min 0.78 ± 0.16 0.62 ± 0.15 0.0001*
Day 28
30 min 0.73 ± 0.095 0.59 ± 0.08 0.0004*
60 min 0.67 ± 0.12 0.53 ± 0.008 0.0004*
RL right lung, LL left lung, Li liver
* p B 0.05
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The RL/Li, LL/Li ratios at 4 and 24 h and p values of
rats in group 4 are given in Table 4. Statistically significant
differences were observed in the RL/Li and LL/Li ratios
acquired from the scintigraphic images of the three positive
control rats, taken 24 h after the administration of HCl
(p \ 0.03) (Fig. 3). Although the RL/Li ratio was higher
than the LL/Li ratio at 4 h, the difference was not statis-
tically significant (p [ 0.05).
The RL/Li, LL/Li ratios and p values of rats in group 5
are given in Table 5. Isotonic saline was administered to
the right lung of this group of rats and no significant dif-
ference was observed between the RL/Li and LL/Li ratios
(p [ 0.05).
Histological findings
The acute changes in the lung tissues of the subjects were
examined. For histological analysis, as explained in the
‘‘Materials and methods’’, the lung tissue was evaluated on
the basis of interstitial edema, vascular congestion,
destruction of the alveolar structure and infiltration by
inflammatory cells. At low magnification (Fig. 1), group 5
showed minimal or technical damage and group 4 showed
all kinds of pathological findings in the right lung. When
groups 1 and 5 were compared histologically, a statistically
significant difference was observed (p \ 0.01). When
groups 2 and 3 were compared with groups 5 and 1, more
significant pathological changes were observed in groups 2
and 3 (p \ 0.001) (Fig. 4). When group 2 was compared
with group 3, the lung damage was similar in both groups.
Administration of HCl led to more extensive lung damage
than any other group (Table 4).
Fig. 2 Anterior scintigraphic images of the rats that received
bleomycin, obtained at 30 and 60 min using Tc-99m HMPAO
14 days after the administration and the areas of interest
Table 4 RL/Li, LL/Li ratios and p values of rats in group 4
Hydrochloric acid (3 rats)
RL/Li LL/Li p value
4 h
30 min 0.71 ± 0.06 0.65 ± 0.09 0.09
60 min 0.76 ± 0.20 0.69 ± 0.16 0.16
24 h
30 min 0.58 ± 0.13 0.52 ± 0.11 0.03*
60 min 0.70 ± 0.23 0.58 ± 0.20 0.02*
RL right lung, LL left lung, Li liver
* p B 0.05
Fig. 3 Anterior scintigraphic images of the positive control rats that
received HCl, obtained at 30 and 60 min using Tc-99m HMPAO, 4 h
after the administration and the areas of interest
Table 5 RL/Li, LL/Li ratios and p values of rats in group 5
Serum physiologic (8 rats)
RL/Li LL/Li p value
Day 7
30 min 0.67 ± 0.21 0.66 ± 0.18 0.58
60 min 0.67 ± 0.18 0.68 ± 0.17 0.80
Day 14
30 min 0.63 ± 0.18 0.64 ± 0.20 0.22
60 min 0.62 ± 0.16 0.63 ± 0.15 0.20
Day 21
30 min 0.60 ± 0.10 0.61 ± 0.10 0.17
60 min 0.68 ± 0.14 0.68 ± 0.14 0.30
Day 28
30 min 0.66 ± 0.15 0.66 ± 0.14 0.75
60 min 0.70 ± 0.10 0.70 ± 0.10 0.23
RL right lung, LL left lung, Li liver
* p B 0.05
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Discussion
Amiodarone is a highly effective antidysrhythmic agent
though it has numerous adverse effects, the most critical of
which is pulmonary toxicity and consequent mortality.
Processes contributing to the development of amiodarone-
induced pulmonary toxicity include phospholipidosis,
changes in calcium ion regulation, generation of reactive
oxygen species or an amiodarone aryl radical, perturbation
of cellular energy production and an immune response to
the parent compound or to a metabolite [22].
With potent tumor-killing properties, bleomycins play
an important role in cancer chemotherapy. Pulmonary
toxicity is one of its major adverse effects. The bleomycin
molecule can either intercalate into the DNA helix and
separate the strands or bind iron and oxygen and form an
activated complex that can release oxidants to the poly-
nucleotide chains of DNA. Bleomycin can also cause cell
damage by inducing lipid peroxidation. This may be
especially important for the lung since it causes alveolar
cell damage, interstitial edema, infiltration by immune
cells, pulmonary inflammation and pulmonary fibrosis [6].
Fig. 4 Panel of images showing the changes observed in lung tissue
when saline (a), single-dose amiodarone (b), two-dose amiodarone
(c), bleomycin (d) and hydrochloric acid (e), which served as positive
control were administered. Increase in tissue edema, inflammatory
cell infiltration, vacuolization within the alveoli and wall damage can
be observed from a to e. HE 9200
596 Ann Nucl Med (2013) 27:592–599
123
A wide range of radiopharmaceuticals, including Tc-
99m diethylenetriaminepentaacetate (Tc-99m DTPA) [23–
26], gallium 67 (Ga-67) [23, 27, 28], I-123 metaiodoben-
zylguanidine (MIBG) [29], I-123 iodoamphetamine (IMP),
I-123 N, N, N-trimethyl-N-[2-hydroxy-3-methyl-5 iodob-
enzyl-1,3 propanediamine (HIPDM) and Tc-99m HMPAO
[1–5, 29–33] are used to determine microvascular injuries
in the lungs. I-123 MIBG, I-123 IMP, I-123 HIPDM and
Tc-99m HMPAO are able to show the endothelial injury in
the lungs scintigraphically [3–5]. Tc-99m HMPAO has
been used in numerous studies for the imaging of chemical
agent- and disease-induced lung damage [1–5, 29–33]. The
simplicity of the procedure, physical characteristics, low-
cost and lower radiation exposure are the advantages of Tc-
99m HMPAO lung scan over Ga-67 scintigraphy and high
resolution CT [28].
Various studies showed the effectiveness of HMPAO in
detecting minimal endothelial lesions in the lungs. Tc-99m
HMPAO is a lipophilic agent with a 380 Da molecular
weight and basic and cyclic amino structure. Essentially, it is
localized in the lungs in the endothelium [5, 32]. Conven-
tional imaging methods cannot show the damage in pul-
monary vascular endothelium in its early stages. Tc-99m
HMPAO can penetrate through the pores in the cell mem-
brane easily due to its lipophilic structure and can reach the
endothelial cytoplasm [5]. Moreover, blood flow, presence
of the alveolar macrophage and intracellular metabolism
changes that may lead to a change in the glutathione help the
agent to depict early and minimal lung damage [1, 5, 32].
Maintenance of the lipophilic structure and appropriate
lung perfusion are the prerequisites for Tc-99m HMPAO to
reach the endothelial cells. It is shown that Tc-99m
HMPAO can penetrate into the broncho-alveolar liquid. It is
believed that Tc-99m HMPAO uptake mostly takes place
through the penetration to the macrophage [32]. Pulmonary
inflammation plays an important role in pulmonary toxicity.
In the present study, as a result of the above-listed
mechanisms, groups 1, 2, 3 and 4 had higher RL/Li ratios
than the LL/Li ratios in the Tc-99m HMPAO lung scans. In
group 5, RL/Li ratio was comparable to the LL/Li ratio. We
believe that the reason why no significant difference was
observed between RL/Li and LL/Li ratios in group 4 at 4th
hour, despite the onset of inflammation at 4th hour, was type
2 macrophages being able to compensate for it. Necrosis
and inflammation occurs at 24th hour, therefore, the scin-
tigraphic values showed a significant difference at this time.
The RL/Li and LL/Li ratios in groups 1 and 2 did not
yield a statistically significant difference; however, mean
RL/Li values were higher than mean LL/Li values.
Suga et al. [5] detected early microvascular endothelial
lung toxicity induced by radiation and chemical agents by
Tc-99m HMPAO. Durmus-Altun et al. [23] studied AD-
induced lung toxicity and administered rats AD
intraperitoneally for 6 weeks and assessed lung toxicity
using a
Tc-99m DTPA inhalation scintigraphy. The present study
differs from the study by Durmus-Altun et al. methodo-
logically, as we have administered AD to the lungs through
a catheter by opening a tracheostomy and imaging the
pulmonary toxicity by Tc-99m HMPAO lung scintigraphy.
Kaya et al. [4] conducted a study investigating AD-
induced lung toxicity in 3 groups of rats by Tc-99m
HMPAO and they have administered AD by gavage at a
dose of 10, 50 and 150 mg/kg/day. Their Tc-99m HMPAO
uptake ratio was consistent with histopathological findings
of AD-induced lung toxicity. In the present study, we also
found results consistent with histopathological findings.
Rats that were administered a single dose of AD, double
dose of AD and BLM into the right lungs showed inter-
stitial pulmonary fibrosis (IPF) in the histopathological
examinations, whereas rats that were administered SF
showed no pulmonary fibrosis.
Kaya et al. [34] conducted another study in which they
have administered low doses of AD (5 mg/kg/day) for
6 months to New Zealand type rabbits through gavaging and
again investigated lung toxicity by Tc-99m HMPAO. They
observed non-specific scintigraphic and histopathological
changes. The present study differs from the study by Kaya
et al. methodologically as we have administered AD to the
lungs through a catheter by opening a tracheostomy. Our
results were also consistent with histopathological findings.
De Azambuja et al. [35] examined by Tc-99m DTPA
inhalation scintigraphy 12 cases with germ cell tumors or
Hodgkin lymphoma, without pulmonary disease, and had
BLM as part of their chemotherapy regime. They found a
significant decrease when post-treatment Tc-99m DTPA
clearance half time (t) was compared with pre-treatment
values.
In the present study, we have investigated the effects of
drug-induced acute lung inflammation and fibrosis. The
characteristic feature of drug-induced pulmonary fibrosis is
the collagen deposit in alveolar walls, which disrupts the
gas exchange and limits the normal functions of the lungs
[36, 37]. There are three stages of histopathological dam-
age in the lungs: early, late and permanent. The early stage
is an exudative stage and is characterized by interstitial and
intra-alveolar edema, bleeding, neutrophil accumulation,
fibrin plasma proteins and hyaline membranes of surfac-
tant. At fine structure level, swollen capillaries, necrosis in
the endothelium and Type 1 alveolar epithelial cells, dis-
tortion of the basal lamina are observed. In late and fi-
broproliferative stage, a cuboidal metaplasia that shows
itself as an increase in Type 2 alveolar epithelial cells,
alveolar wall thickening and fibrosis is observed. The
edema starts initially in the bronchus and large vein walls
and diffuse on to the alveolar wall interstitium and finally
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to the alveolar cavity. Reactive oxygen radicals (ROR) and
proteases are usually secreted from these inflammatory
cells and cause a damage in the lungs, and during the
regeneration phase, an extreme fibrosis develops [38, 39].
Studies show that in drug-induced toxicities, lung
damage starts in the bronchioles and at the end of the first
week extend to the parenchyma. In the case of bleomycin
administration, it is observed that after 15 days, inflam-
mation decreases, collagen accumulation and cystic areas
and round cells dominate. 30 days after the administration,
fibrosis settles in the areas where there was inflammation.
120 days after the administration, emphysematous changes
take place, alveoli expand and the walls rupture.
Macrophage inflammatory protein-1a (MIP-1a) is a
protein with chemotactic properties for interstitial and
alveolar macrophages. Macrophage inflammatory protein 2
(MIP-2), on the other hand, is the murine analog of inter-
leukin-8 (IL-8) which is the neutrophil chemotactic factor
in human beings. Neutrophils play an important role in the
pathogenesis of IPF [40]. It is known that Type 2 cells have
a stronger resistance against pathological insults. Air–
blood barrier is formed by alveoli epithelia, capillary
endothelia and the interstitium between them. The disrup-
tion of this barrier takes place by a change in the thickness
of these three components, swelling and rupturing [21].
These early stage changes are shaped by agents called pre-
inflammation cytokines such as TNF-alpha and IL-1 beta.
For example, antibodies developed against these two fac-
tors may prevent the neutrophil accumulation in the lungs.
Amiodarone is an anti-arrhythmic and its most impor-
tant complication is lung toxicity. Its toxicity is similar to
BLM. It uses similar mechanisms as BLM. It is known that
BLM induces formation of reactive oxygen metabolites
such as superoxide and hydroxyl. These reactive metabo-
lites have numerous effects such as DNA damage, lipid
peroxidation, changes in the synthesis of lung prostaglan-
din, degradation, and increase in the synthesis of lung
collagens [18, 41]. The major area of damage is Type 1
alveoli epithelial cells and pulmonary capillary endothelial
cells. Type 1 pneumocyte damage is followed by Type 2
pneumocyte hyperplasia and dysplasia. Healing process in
drug-induced lung damage is much slower than lung
damage induced by inhalation toxins such as air pollution.
It results initially in infiltration by granulocytes, lympho-
cytes, eosinophils and plasma cells, inflammation and
cytokine release [42]. In the pathogenesis of bleomycin-
induced lung disease, transforming growth factor-b (TGF-
b), tumor necrosis factor-a (TNF-a), IL-1, IL-5, IL-6,
platelet-derived growth factor (PDGF) and a variety of
cytokines such as chemokines play important roles. In rats
treated with bleomycin, TGF-b mRNA accumulates in the
alveolar macrophages while anti TGF-b antibody admin-
istration minimizes the drug-induced pulmonary reactions.
Similarly, BLM-sensitive IL-1 and TNF-a are produced in
increasing amounts, and IL-1 receptor antagonists, anti-
TNF antibodies and soluble TNF receptors alleviate the
bleomycin-induced pulmonary fibrosis [42]. As a result of
bleomycin-induced damage, inflammation and cytokine
deregulation, fibroblasts are activated. Fibroblast and
myofibroblast production increases, collagen degradation
becomes inhibited leading to an increase in collagen pro-
duction and fibrosis develops. As a result, cytotoxic drug-
induced pulmonary damage is manifested by interstitial
inflammation and fibrosis [42, 43].
In conclusion, the findings of this study showed that a
significant toxicity developed especially in group 2 that
received a double dose of AD and group 3 that received
BLM. We believe that understanding the underlying
mechanisms of this toxicity will provide valuable infor-
mation for diminishing the side effects of medications. We
also conclude that Tc-99m-HMPAO lung scintigraphy is a
simple, sensitive and an objective method for the detection
of drug-induced lung toxicity. This method also has the
advantages of low-cost and low radiation exposure, when
compared to Ga-67 scintigraphy and high resolution CT.
Using Tc-99m HMPAO scintigraphy, we can easily detect
drug-induced pulmonary toxicity caused by amiodarone or
bleomycin even in the early stages, thus necessary pre-
cautions can be undertaken.
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